Monoclonal Antibody Production via Glycopeptide Capture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing antibodies that target glycan sites on glycoproteins are limited by their ability to recognize chemically synthesized glycans rather than those bound to proteins in vivo, restricting their application to actual glycoproteins in biological samples.
Innovation Solution
A method involving proteolysis of glycoproteins to obtain peptide fragments, treatment with hydrazide beads to capture glycan-containing glycopeptides, and identification of monoclonal antibodies using phage antibody display technology, allowing for the production of antibodies that specifically recognize glycan binding sites on glycoproteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemically synthesized glycans are used for antibody development, then antibody production is simplified, but the antibody cannot recognize glycan sites on actual glycoproteins in vivo
Solution Approach 1:
The patent uses chemically synthesized glycans as intermediaries to immunize animals and generate antibodies. These synthetic glycans serve as a bridge between the simplified production process and the ultimate goal of creating antibodies that recognize glycan sites on actual glycoproteins in vivo. The antibodies generated through this intermediary approach successfully bind to glycan-containing peptides and full-length glycoproteins, resolving the contradiction between ease of manufacture and recognition capability.
2Reliability
If glycoproteins are directly used for antibody screening, then antibodies can recognize actual glycoproteins, but the complexity of handling and purifying glycoproteins increases
Solution Approach 1:
The patent segments the glycoprotein into smaller glycan-containing peptides through proteolytic digestion. This segmentation simplifies the screening process by creating smaller, more manageable targets that can be easily synthesized and used for phage display screening, while still maintaining the ability to generate antibodies that recognize the glycan sites on full-length glycoproteins.
3Productivity
If short-length glycopeptides are used for phage display, then screening efficiency improves, but the structural context of the glycan may be lost
Solution Approach 1:
The patent applies local quality by focusing the antibody screening on the specific glycan-containing regions of the glycoprotein while maintaining the local structural context necessary for recognition. The glycan-containing peptides are designed to preserve the critical local structural features around the glycan site, ensuring that antibodies generated against these peptides can recognize the corresponding sites on full-length glycoproteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the efficient production of monoclonal antibodies that recognize glycan binding sites on glycoproteins with high specificity, facilitating their use in disease diagnosis and treatment by targeting altered glycosylation patterns associated with diseases such as cancer.
Implementation Method 1
treatment with hydrazide beads or hydrazide nanoparticles to capture a glycan-containing glycopeptide
Data Source
AI summary
The present disclosure relates to a method for producing a monoclonal antibody that binds to an epitope for the glycan binding site of a glycoprotein. According to the present disclosure, a monoclonal antibody that recognizes the glycan binding site of a glycoprotein as an epitope can be produced in a relatively simple and economic manner, and a monoclonal antibody having high sensitivity and specificity for the glycan binding site of a glycoprotein can be produced. The monoclonal antibody produced according to the present disclosure can be effectively used as an agent for diagnosing or treating various diseases associated with a change in glycan structure or glycan expression level.